Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Notes Payables (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 15 years of Notes Payables data on record, last reported at $13.6 million in Q3 2025.

  • For Q3 2025, Notes Payables rose 79.09% year-over-year to $13.6 million; the TTM value through Sep 2025 reached $13.6 million, up 79.09%, while the annual FY2024 figure was $14.2 million, 259.69% up from the prior year.
  • Notes Payables reached $13.6 million in Q3 2025 per NWBO's latest filing, down from $16.3 million in the prior quarter.
  • Across five years, Notes Payables topped out at $20.0 million in Q3 2022 and bottomed at $2.2 million in Q1 2021.
  • Average Notes Payables over 5 years is $10.8 million, with a median of $9.9 million recorded in 2022.
  • The widest YoY moves for Notes Payables: up 5162.22% in 2021, down 78.68% in 2021.
  • A 5-year view of Notes Payables shows it stood at $7.1 million in 2021, then skyrocketed by 116.82% to $15.4 million in 2022, then plummeted by 74.39% to $3.9 million in 2023, then skyrocketed by 259.69% to $14.2 million in 2024, then fell by 4.34% to $13.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Notes Payables were $13.6 million in Q3 2025, $16.3 million in Q2 2025, and $19.6 million in Q1 2025.